About Edoardo G.

Edoardo G. Giannini is Professor of Gastroenterology at the Department of Internal Medicine of the University of Genoa, Italy.

Professor Giannini earned his medical degree in 1995 and was board-certified in Gastroenterology in 1999 at the University of Genoa, Italy, where he also obtained a PhD in Clinical and Experimental Gastroenterology. Professor Giannini studied the anatomo-functional correlates in large cohorts of patients with hepatitis C virus (HCV) infection, and his studies led to the development of non-invasive models to assess severity of chronic liver disease.

His research interests are mainly centered upon viral hepatitis and advanced liver disease, including liver cancer. He has been the recipient of clinical research grants, and has led several clinical trials. He authored or co-authored more than 200 peer-reviewed publications in the field of gastroenterology and hepatology, and served as associate editor of hepatology journals.

Professor Giannini currently serves as the Secretary General of the Italian Association for the Study of the Liver (AISF).

This speaker will be presenting at the following session(s)

  • Options for countries without access to generic hepatitis medicines

    Ballroom 1

    Day: 2 November

    Time: 12:00

    Chairs: Ellen ‘t Hoen, University of Groningen, Netherlands and Dr. Massimo Ghidinelli, World Health Organization

    Presentations:

    • Introduction to Intellectual Property.
      Ellen ‘t Hoen, University of Groningen, Netherlands
    • Patent opposition.
    • Olivier Maguet, Médecins du Monde
    • Malaysian strategy for access to HCV DAAs: road to compulsory licensing.
    • Shangeetha Thirumayni, Malaysian AIDs Council
    • How the interplay among scientific societies, medicines agency, and patients associations favoured drug price negotiation and allowed universal treatment of HCV: the Italian experience.
      Prof. Edoardo G. Giannini, University of Genoa, Italy
    • PAHO Strategic Fund - pooled procurement to improve access to high cost hepatitis medicines in commercial markets.
    • Juliana Vallini, Pan American Health Organization
    • Q & A session.